Back to Top

There is a Mary Ann Liebert at Mary Ann Liebert, Inc. and that makes a difference.

For Immediate Release

New Peer-Reviewed Journal PHAGE: Therapy, Applications, and Research Announced, Preview Issue Launching Summer 2019

Contact: Kathryn Ryan
914-740-2250
kryan@liebertpub.com

Mary Ann Liebert, Inc.
140 Huguenot Street
New Rochelle, NY 10801
(914) 740-2100 or (800) M-LIEBERT
Fax (914) 740-2101
www.liebertpub.com

New Rochelle, NY, March 14, 2019Mary Ann Liebert, Inc., publishers announces the launch of PHAGE: Therapy, Applications, and Research, the only peer-reviewed publication dedicated to the burgeoning field of bacteriophage research and its applications in medicine, agriculture, aquaculture, veterinary applications, animal production, food safety, and food production. Spearheaded by Editor-in-Chief, Martha Clokie, PhD, Professor of Microbiology, University of Leicester, UK, PHAGE will be published quarterly online and in print and will serve as the cornerstone publication of phage research with the goal of solidifying, growing, and unifying its emerging community of innovative researchers and clinicians. A preview issue of the Journal is planned for summer 2019.

The therapeutic use of bacteriophages first emerged more than a century ago but waned in the West with the advent of antibiotics. Now, with antibiotic resistance identified as an urgent public health crisis, phage therapy has reemerged as a key to treating and preventing antibiotic-resistant infections. PHAGE will not only advance this area of research but will also open doors for new ideas and pique the interest of funding agencies to procure more money for scientists and clinicians vested in bacteriophages. Phage therapy was the topic of the March cover story of Genetic Engineering & Biotechnology News, the leading publication in the field and also published by Mary Ann Liebert, Inc.

“Bacteriophages are the most abundant bacterial predators on Earth, and we can think of them collectively as being a giant under-explored treasure chest of solutions to treat bacterial diseases,” says Dr. Clokie. “We have never had so many tools at our fingertips to unravel phage biology in order to inform their development as new solutions to the antimicrobial resistance crisis. I’m extremely excited to take up the position of Editor-in-Chief for the journal PHAGE, which aims to act as a cornerstone publication and resource for bacteriophage researchers by capturing the most exciting developments in phage biology.”

PHAGE will provide a powerful platform for the deliberation and dissemination of phage research, in the form of impactful original research articles, reviews, commentaries, perspectives, and profiles. The Journal will include and promote the ethical, regulatory, and policy challenges faced by the research community and will be the critical resource for molecular biologists, microbiologists, bacteriologists, bioengineers, immunologists, clinicians and translational biologists and unify this evolving cluster of innovative researchers, industry leaders, clinicians and policy makers.

Topics covered in PHAGE will include: Life cycle of phages; capsid structure and morphology; genome organization and content; phage transcriptional takeover and regulation; roles of phages in natural ecosystems; impacts of phages on bacterial/eukaryotic physiology; immune cell modulation by phages; multidrug and antibiotic resistance; regulation of gut microbiota and GI infections; regulation of lung/skin/bladder/blood/bone and other infections; application of phages post-surgery; genetic engineering of phages; roles of synthetic phages to manipulate inflammation and cancer; impact and exploitation of CRISPR-Cas systems; phages as vectors for gene delivery; vaccine development; phage based diagnostics; phage proteins and enzymes; bacteriophage lysins; phage therapy in plants; phage therapy in aquaculture and fisheries; phages and food production and safety; nanotechnology and materials science; drug, gene, and antibody delivery; novel model systems to study phage behavior; clinical and animal trials; phage therapy ethical and regulatory challenges; and phage therapy policy.

For complete information, to sign up for email alerts, or to submit your manuscript, please visit the PHAGE website.

About the Publisher

Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative medical and biomedical peer-reviewed journals, including Microbial Drug Resistance, Vector-Borne and Zoonotic Diseases, Foodborne Pathogens and Disease, Viral Immunology, Advances in Wound Care, Surgical Infections, DNA and Cell Biology, and The CRISPR Journal. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), remains the industry’s most respected and widely read publication worldwide. A complete list of the firm’s more than 80 journals, newsmagazines, and books is available on the Mary Ann Liebert, Inc., publishers website.

 

 

Mary Ann Liebert, Inc.
140 Huguenot Street
New Rochelle, NY 10801
(914) 740-2100 or (800) M-LIEBERT
Fax (914) 740-2101
www.liebertpub.com